Document Detail

Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia.
Jump to Full Text
MedLine Citation:
PMID:  21029529     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 1999, a review of the literature for 1966-1997 suggested that ≈1.1 million persons die annually of shigellosis, including ≈880,000 in Asia. Our recent review of the literature for 1990-2009 indicates that ≈125 million shigellosis cases occur annually in Asia, of which ≈14,000 are fatal. This estimate for illnesses is similar to the earlier estimate, but the number of deaths is 98% lower; that is, the lower estimate of deaths is associated with markedly reduced case-fatality rates rather than fewer cases. Shigella spp.-related deaths decreased substantially during a period without Shigella spp.-specific interventions. We speculate that nonspecific interventions, e.g., measles vaccination, vitamin A supplementation, and improved nutrition, may have led to the reduced number of shigellosis-related deaths.
Authors:
Pradip Bardhan; A S G Faruque; Aliya Naheed; David A Sack
Related Documents :
19132549 - Palliative sedation until death: an approach from kant's ethics of virtue.
1545199 - U.s. navy and marine corps recruit training deaths in san diego, california, 1973-1985;...
2063819 - Cerebrovascular malformation causing sudden death. analysis of three cases and review o...
11327229 - Death due to inhalation of industrial acetylene.
9231989 - Sudden death due to paragonimus kellicotti infection in a dog.
12960669 - Unusual facial markings and lethal mechanisms in a series of gasoline inhalation deaths.
6702919 - Nonimmunologic hydrops fetalis.
9400439 - Ureteropelvic junction disruption secondary to blunt trauma: excretory phase imaging (d...
15384799 - Relapsing peritonitis in continuous ambulatory peritoneal dialysis and an unconventiona...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Emerging infectious diseases     Volume:  16     ISSN:  1080-6059     ISO Abbreviation:  Emerging Infect. Dis.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-29     Completed Date:  2011-03-02     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  9508155     Medline TA:  Emerg Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1718-23     Citation Subset:  IM    
Affiliation:
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Asia / epidemiology
Dysentery, Bacillary / epidemiology*,  mortality*,  prevention & control
Humans
Shigella / classification*
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Emerg Infect Dis
Journal ID (publisher-id): EID
ISSN: 1080-6040
ISSN: 1080-6059
Publisher: Centers for Disease Control and Prevention
Article Information
Download PDF

Print publication date: Month: 11 Year: 2010
Volume: 16 Issue: 11
First Page: 1718 Last Page: 1723
ID: 3294502
PubMed Id: 21029529
Publisher Id: 09-0934
DOI: 10.3201/eid1611.090934

Decreasing Shigellosis-related Deaths without Shigella spp.–specific Interventions, Asia Alternate Title:Decreasing Shigellosis-related Deaths
Pradip Bardhan
A.S.G. Faruque
Aliya Naheed
David A. Sack
Author affiliations: International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh (P. Bardhan, A.S.G. Faruque, A. Naheed);
Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA (D.A. Sack)
Correspondence: Address for correspondence: David A. Sack, Department of International Health, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe St, Rm E5537, Baltimore, MD 21205, USA; email: dsack@jhsph.edu

In 1999, Kotloff et al. reviewed the literature to estimate the global incidence of shigellosis. On the basis of studies published during 1966–1997, they estimated ≈1.1 million shigellosis-related deaths annually, resulting from ≈164.7 million cases. Of these, ≈163.2 million cases occurred in developing countries, ≈80% of which occurred in Asia (1). These high estimates of illness and death have increased interest in identifying interventions, including new vaccines, that might reduce these astonishing numbers (25).

Several changes have occurred that might have altered this incidence. Shigellosis might be increasing because of increasing populations in Shigella spp.–endemic areas; because of increasing resistance to antimicrobial drugs among shigellae, especially in S. dysenteriae type 1 (the Shiga bacillus) (68); or because of increasing rates of HIV infection and AIDS in many countries, which might be influencing shigellosis incidence. On the other hand, incidence might be decreasing because of improved nutrition in many countries, improved delivery of healthcare in some areas, and more widespread use of measles vaccine (9,10) and vitamin A supplementation (11), which might reduce the severity of intestinal infections. The availability of fluoroquinolones, often used without prescription, also might lead to changing treatment practices because families might use antimicrobial drugs earlier during diarrheal illness or for other illnesses (12).

Shigellosis incidence might also have changed because of the overall reduction in diarrhea-related deaths through case management, including rehydration therapy and proper feeding (13). Because shigellosis is not primarily a dehydrating condition, hydration is not critical for patients with dysentery. Nonetheless, the consistent use of oral rehydration therapy for diarrhea may reduce illness from the persistent effects of repeated episodes of diarrhea, which is common in developing counties.

Thus, at the request of the World Health Organization, we reviewed the literature for 1990–2009 to estimate the current incidence of shigellosis. The earlier study by Kotloff et al. attempted to extrapolate from data from developing countries; however, most of the data were from Asia. Because the epidemiology of shigellosis may differ in Africa, we restricted our review to studies in Asian populations.


Materials and Methods

Our review comprised studies identified through Medline. The initial studies were identified by a computer search of the multilingual scientific literature published since 1990. Articles derived by using the keywords Shigella, dysentery, bacillary, and shigellosis were linked with a set of other articles obtained by using the keywords incidence, prevalence, public health, death rate, mortality, surveillance, burden, distribution, and permutations of the root word epidemiol-. We conducted searches for each Asian country, except Japan and Israel. The resulting cross-linked set contained 319 articles, which we culled to 164 articles that were relevant to the goal of the search. Additional sources were located through consultations with experts in the field, proceedings of expert meetings, and the ongoing Diarrheal Diseases Surveillance Programme of the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B). To enable comparison over time, we adopted the methods of the previous review on shigellosis (1).

We created an algorithm to estimate the number of Shigella infections that occurred each year in Asia. In a preliminary step, the world’s population was divided into 4 age strata (0–11 months, 1–4 years, 5–14 years, and >15 years). Published rates of diarrhea for each of the 4 strata were used to estimate the diarrheal disease incidence. An increase in the severity of a patient’s illness influences the proportion of diarrheal episodes attributable to Shigella spp. This correlation can be presumed to strengthen as the proportion of Shigella infections increases because sampling progresses from cases of diarrhea detected by household surveillance to those among outpatients to persons admitted to hospital (14). Thus, we subdivided the total diarrheal disease incidence into these 3 settings: estimates of mild cases in persons who stayed at home; more severe cases needing care at a clinic but not hospitalization; and cases requiring hospitalization.

The total number of diarrhea cases attributable to shigellosis was calculated for the <1-year and 1–4-year age groups by multiplying the number of diarrhea cases in the 2 settings (community and treatment facilities) by the percentage of diarrhea cases from which Shigella spp. were isolated (Table 1). For older children and adults, we calculated total cases by multiplying the median percentages of diarrhea cases attributable to shigellosis in persons 5–14 years and >15 years of age by the number of diarrhea cases in these 2 age groups according to clinical setting (Table 2).

We adopted the estimates of Kosek et al. (15) to calculate the number of diarrhea episodes per person per year within countries in Asia (Table 1). These estimates were based on the review of 13 longitudinal studies of stable populations in 8 countries in Asia, where active surveillance was conducted during 1984–1995.

We estimated the proportion of diarrheal episodes in each stratum that can be attributed to shigellosis by analyzing only studies in which surveillance was conducted since 1990 and that used microbiologic confirmations to report the percentage of Shigella spp.–related diarrhea cases for the specified age group. An overall median percentage of shigellosis was then calculated for each stratum and multiplied by the total number of diarrheal cases in the stratum to derive the number of shigellosis cases in each stratum. In addition to the median, a weighted mean with 95% confidence intervals (CIs) was calculated for these analyses by using Freeman-Tukey transformed proportions. Weights used were equal to the inverse standard errors of these transformed proportions (18,19). The numbers of shigellosis cases were added to give an overall estimate of shigellosis-related illness. Case-fatality rates (CFRs) for persons hospitalized with Shigella infection at the ICDDR,B hospital were used to calculate age-specific rates of Shigella spp.–associated death. This hospital treats >100,000 diarrhea patients annually and is the same hospital used for CFRs in the earlier study.

Illness was expressed as episodes of diarrhea per person-year from which shigellae were recovered. Studies were included in the death estimates if deaths caused by Shigella spp. could be ascertained through active surveillance. The review comprised prospective and retrospective studies but not studies based on vital statistics only. Death was considered to have been caused by diarrhea only if diarrhea was listed as the primary cause.


Results

Approximately 3,938,020,000 persons resided in Asia during 2005. This estimate included 78,533,000 infants <1 year of age and 361,252,000 children 1–4 years of age (20,21).

Shigellosis Incidence

The median frequency of Shigella spp. isolation from diarrheal cases in the community in children 0–4 years of age was 4.4% (range 3.1%–13.4%; weighted mean 5.1%, 95% CI 4.4%–5.7%). Because only 1 study broke this rate down into the <1-year and 1–4-year ranges, the median of the 2 values for the combined range was calculated. The median frequencies of Shigella spp. isolation rates from persons with diarrhea reporting to the treatment facilities were 5.8% (range 2.4%–9.3%) among children <1 year of age and 9.4% (range 2.4%–23.5%) among children 1–4 years of age. The weighted mean of the combined group was 6.6% (95% CI 6.0%–7.2%). Details of these studies are found in Technical Appendix Tables 1, 2).

Approximately 39,669,000 (weighted mean 45,980,000, 95% CI 39,669,000–51,389,000) shigellosis cases occurred in children <5 years of age in the community and 6,671,000 (weighted mean 5,433,000, 95% CI 5,256,000–5,927,000) in treatment facilities, totaling 46,717,000 (95% CI 44,924,000–57,316,000) cases among Asian children <5 years of age annually. The proportions of cases with shigellosis are detailed in Technical Appendix Tables 1, 2.

The median percentage of diarrhea in the community was 4.0% (range 1.6%–13.5%; weighted mean 4.6%, 95% CI 4.0%–5.1%). The median percentages for patients treated at facilities were ≈11.6% (range 4.7%–17.3%) and ≈10.7% (range 4.1%–27%) respectively (weighted mean of the combined groups 8.3%, 95% CI 7.7–9.0%). (The proportions of shigellosis cases are detailed in Technical Appendix Table 3, 4.) Shigella infections among children 5–14 years of age and persons >15 years of age were ≈20,049,000 (95% CI 19,673,000–24,898,000) and ≈58,576,000 (95% CI 57,726,000–73,057,000), respectively.

We combined the number of shigellosis episodes in all age groups. The total annual number of shigellosis cases in Asia was ≈125 million (95% CI 122 million–155 million).

Shigellosis-associated Deaths

Median CFRs for hospitalized shigellosis patients <1 year and 1–4 years of age and patients >5 years of age were 0.89%, 0.01%, and 0 respectively (Table 3), according to data from the ICDDR,B hospital surveillance program during 1990–2007. The weighted means for patients <1 and 1–4 years of age were 0.8% (95% CI 0.5%–1.0%) and 0.1% (95% CI 0.02%–0.25%), respectively. No deaths were reported from large studies in other countries in Asia. By using median CFRs from Bangladesh for these age groups, we determined that ≈1,960 shigellosis deaths occurred in Asia among hospitalized patients annually (Table 3). By using the 95% CIs, we estimated that the number of deaths ranged from 1,347 to 2,595.

A study from Bangladesh found that only 17.8% of shigellosis-related deaths occurred in treatment facilities; another study from the Gambia reported that only 12% of deaths associated with Shigella infection among children occurred in a health center (23,24). Thus, the true number of shigellosis-associated deaths may be 6–8× higher than deaths recorded in the hospital records. Hence, the estimates of the in-hospital shigellosis-associated deaths were multiplied by a factor of 7 in all age groups to correct for out-of-hospital mortality. This increased the number of deaths in all age groups to ≈13,720 shigellosis-related deaths across all the age groups per year in Asia (Table 4).


Discussion

Our review calculated that ≈125 million cases of endemic shigellosis occur annually in Asia, of which ≈14,000 (0.011%) cases result in death. Children <5 years of age are at highest risk for Shigella spp.–related illness and death. Although this estimate suggests that shigellosis incidence is substantial and similar to the earlier estimate, the updated death estimate is 98% lower than the estimate by Kotloff et al. (1) that used data primarily from the 1980s. Assuming that the population of Asia is ≈80% of the total population of the developing countries, ≈130 million Shigella infections and ≈880,000 deaths occurred in Asia according to the earlier estimate.

With such a large difference in estimated incidences, one estimate may be more accurate than the other. Alternatively, Shigella spp.–related deaths may have decreased substantially since the 1980s, even in the absence of specific interventions against shigellosis. We believe the latter explanation best explains the large difference in estimates of deaths.

The major variable that was lower in our calculations was the CFR for hospitalized patients, especially children. In the earlier estimate, a CFR of 11% was used from the ICDDR,B hospital (24). Recent data from the same hospital indicate the rate is now ≈0.01% overall and only 0.89% for the youngest age group. A recent estimate from Africa found a CFR of <1% during an outbreak associated with S. dysenteriae, suggesting that this low CFR may not be limited to Asia (25).

The decrease in CFRs could be explained by >1 factor. Case management might have improved, strains might be less virulent, or children might be healthier when they become infected and therefore have less severe complications. Case management in the hospital is unlikely to have changed substantially, and in fact the increasing resistance of current strains to antimicrobial drugs makes case management more difficult. Case management in the home may have changed, however, because antimicrobial drugs are widely available, and families may purchase effective antimicrobial drugs, e.g., ciprofloxacin, and begin treatment earlier in the course of the illness (12). Virulence of infecting strains could be lower; infections with S. dysenteriae type 1 are unusual. During past epidemics with this serotype, however, the CFR for S. flexneri was as high as it was with S. dysenteriae type 1 (24). Thus, virulence is unlikely to explain the decrease in the number of deaths.

Improved health of children who become infected appears to best explain the decreased CFR. Nutritional status of children in Bangladesh has continued to improve slowly (26). Perhaps more essential is the high proportion receiving measles vaccine and vitamin A (27). Anecdotally, in children dying of shigellosis during the 1980s, postmeasles dysentery was often diagnosed, and measles increased the severity of diarrhea, including shigellosis (9,10). Measles with dysentery is rarely seen now in Bangladesh.

Our review has some limitations. Although we reviewed all available published data on shigellosis in Asia since 1990, few sites conduct active surveillance for this infection, and only one estimates CFRs. With this large population, extrapolating accurately to the entire continent might not be possible. Nevertheless, the same methods were used in this and the earlier review. The large multicenter study on shigellosis in Asia did not record any deaths, suggesting that fatalities from shigellosis are not common (22).

Second, the review included only Asia, and the situation in Africa is possibly (even likely) different (28). The higher rates of HIV infection and AIDS and malaria, different nutritional deficiencies, different rates of measles vaccination, and different health systems and civil disturbance might suggest higher Shigella spp.–related deaths in Africa. Unfortunately, until recently, no long-term surveillance for diarrhea has existed in Africa on which to base estimates.

Third, the data in the review were based on microbiologic diagnosis of Shigella infections. Although isolation of Shigella spp. from fecal samples is the most specific diagnostic test for shigellosis, the culture method has limited sensitivity because of the relatively fastidious nature of the organism. Adoption of improved specimen transport methods and newer and more sensitive molecular laboratory diagnostic methods (e.g., PCR) reportedly having high sensitivities may detect more infections (29) but is unlikely to alter the death estimates.

The remarkable 98% decrease in deaths from shigellosis in the absence of a Shigella spp.–specific intervention suggests that other nonspecific interventions have helped to lower Shigella spp.–specific deaths. These, we believe, include measles vaccine, vitamin A supplements, and overall improvement in nutrition. Although the ready availability of antimicrobial drugs encourages the development of antibiotic drug resistance because of frequent abuse, we cannot rule out the possibility that the rapid availability of these antibiotics (especially fluoroquinolones) also have benefited children with dysentery who may be receiving treatment more quickly than they previously did.

The findings from our review may provide lessons regarding other infectious diseases. Approximately 50% of deaths among children <5 years of age have malnutrition as an underlying cause (30). Also, malnutrition and infection are clearly related, with one leading to the other. By reducing rates of other common infections, e.g., measles, and improving the nutritional status, including micronutrient nutrition, of children, diseases from other infections, such as Shigella spp., may decrease.

The 4 species and numerous serotypes of Shigella spp. are a challenge for vaccine developers, but shigellosis remains high, and increasing resistance to antibiotic drugs continues to make treatment difficult. An effective Shigella spp. vaccine may have substantial benefits, but our study suggests that Shigella spp.–related deaths can be, and have been, substantially reduced with currently available interventions and that such interventions do not need to be Shigella spp. specific.


Supplementary Material Technical Appendix

Proportion and total number of diarrheal episodes data tables.


Click here for additional data file (09-0934-Techapp.pdf)


Notes

Suggested citation for this article: Bardhan P, Faruque ASG, Naheed A, Sack DA. Decreasing shigellosis-related deaths without Shigella spp.–specific interventions, Asia. Emerg Infect Dis [serial on the Internet]. 2010 Nov [date cited]. http://dx.doi.org/10.3201/eid1611.090934

Acknowledgments

We gratefully acknowledge these donors who provide unrestricted support to the Centre’s research: Australian International Development Agency, Government of Bangladesh, Canadian International Development Agency, Government of the Netherlands, Swedish International Development Cooperative Agency, Swiss Development Cooperation, and Department for International Development, UK. We also acknowledge statistical assistance of Richard E. Thompson.

This activity was funded by a grant from the World Health Organization and by core funds of the ICDDR,B.

Dr Bardhan is a senior scientist and physician at the International Centre for Diarrhoeal Disease Research, Bangladesh. He is involved in clinical care and clinical research.


References
1. . KotloffKL, WinickoffJP, IvanoffB, ClemensJD, SwerdlowDL, SansonettiPJ, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.Bull World Health Organ. Year: 1999;77:651–6610516787
2. . AshkenaziS, PasswellJH, HarlevE, MironD, DaganR, FarzanN, et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O–specific polysaccharide conjugates in children.J Infect Dis. Year: 1999;179:1565–810.1086/31475910228084
3. . KotloffKL, TaylorDN, SzteinMB, WassermanSS, LosonskyGA, NataroJP, et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.Infect Immun. Year: 2002;70:2016–2110.1128/IAI.70.4.2016-2021.200211895966
4. . KatzDE, CosterTS, WolfMK, TrespalaciosFC, CohenD, RobinsG, et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.Infect Immun. Year: 2004;72:923–3010.1128/IAI.72.2.923-930.200414742537
5. . AltboumZ, BarryEM, LosonskyG, GalenJE, LevineMMAttenuated Shigella flexneri 2a delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.Infect Immun. Year: 2001;69:3150–810.1128/IAI.69.5.3150-3158.200111292735
6. . SackRB, RahmanM, YunusM, KhanEHAntimicrobial resistance in organisms causing diarrheal disease.Clin Infect Dis. Year: 1997;24(Suppl 1):S102–510.1093/clinids/24.Supplement_1.S1028994788
7. . BhattacharyaSK, SarkarK, BalakrishNG, FaruqueAS, SackDAMultidrug-resistant Shigella dysenteriae type 1 in south Asia.Lancet Infect Dis. Year: 2003;3:75510.1016/S1473-3099(03)00829-614652200
8. . DuttaD, BhattacharyaMK, DuttaS, DattaA, SarkarD, BhandariB, et al. Emergence of multidrug-resistant Shigella dysenteriae type 1 causing sporadic outbreak in and around Kolkata, India.J Health Popul Nutr. Year: 2003;21:79–8012751679
9. . KosterFT, CurlinGC, AzizKM, HaqueASynergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh.Bull World Health Organ. Year: 1981;59:901–86978197
10. . MathurR, MathurYN, VermaSDAn outbreak of shigellosis in central India: higher death rate in post-measles shigellosis.J Diarrhoeal Dis Res. Year: 1989;7:28–92607100
11. . MitraAK, AlvarezJO, WahedMA, FuchsGJ, StephensenCBPredictors of serum retinol in children with shigellosis.Am J Clin Nutr. Year: 1998;68:1088–949808227
12. . LarsonCP, SahaUR, IslamR, RoyNChildhood diarrhoea management practices in Bangladesh: private sector dominance and continued inequities in care.Int J Epidemiol. Year: 2006;35:1430–910.1093/ije/dyl16716997849
13. . VictoraCG, BryceJ, FontaineO, MonaschRReducing deaths from diarrhoea through oral rehydration therapy.Bull World Health Organ. Year: 2000;78:1246–5511100619
14. . FerreccioC, PradoV, OjedaA, CayyazoM, AbregoP, GuersL, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile.Am J Epidemiol. Year: 1991;134:614–271951266
15. . KosekM, BernC, GuerrantRLThe global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000.Bull World Health Organ. Year: 2003;81:197–20412764516
16. . PunyaratabandhuP, VathanophasK, VaravithyaW, SangchaiR, AthipanyakomS, EcheverriaP, et al. Childhood diarrhoea in a low-income urban community in Bangkok: incidence, clinical features, and child caretaker’s behaviours.J Diarrhoeal Dis Res. Year: 1991;9:244–91787280
17. . ChenKC, LinCH, QiaoQX, ZenNM, ZhenGK, ChenGL, et al. The epidemiology of diarrhoeal diseases in southeastern China.J Diarrhoeal Dis Res. Year: 1991;9:94–91918839
18. . RothmanKJ, GreenlandS Meta-analysis. In: Modern epidemiology. 2nd ed. Philadelphia, Lippincott-Raven; Year: 1998 p. 660–1.
19. . StuartA, OrdJK Kendall’s advanced theory of statistics. Vol. 1: distribution theory. 6th ed. London: Hodder Arnold; Year: 1994
20. . ParasharUD, HummelmanEG, BreseeJS, MillerMA, GlassRIGlobal illness and deaths caused by rotavirus disease in children.Emerg Infect Dis. Year: 2003;9:565–7210.3201/eid0905.02056212737740
21. . United Nations Population Division World urbanization prospects. The 2007 revision population database. Year: 2008 [cited 2009 Jun 13]. http://esa.un.org/unup/
22. . von SeidleinL, KimDR, AliM, LeeH, WangX, ThiemVD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology.PLoS Med. Year: 2006;3:e35310.1371/journal.pmed.003035316968124
23. . GreenwoodBM, GreenwoodAM, BradleyAK, TullochS, HayesR, OldfieldFSDeaths in infancy and early childhood in a well-vaccinated, rural, west African population.Ann Trop Paediatr. Year: 1987;7:91–92441658
24. . BennishML, WojtyniakBJMortality due to shigellosis: community and hospital data.Rev Infect Dis. Year: 1991;13(Suppl 4):S245–5110.1093/clinids/13.Supplement_4.S2452047645
25. . GuerinPJ, BrasherC, BaronE, MicD, GrimontF, RyanM, et al. Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone.Lancet. Year: 2003;362:705–610.1016/S0140-6736(03)14227-412957094
26. . FaruqueAS, AhmedAM, AhmedT, IslamMM, HossainMI, RoySK, et al. Nutrition: basis for healthy children and mothers in Bangladesh.J Health Popul Nutr. Year: 2008;26:325–3918831228
27. . JamilKM, RahmanAS, BardhanPK, KhanAI, ChowdhuryF, SarkerSA, et al. Micronutrients and anaemia.J Health Popul Nutr. Year: 2008;26:340–5518831229
28. . RamPK, CrumpJA, GuptaSK, MillerMA, MintzED, PartIIAnalysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984–2005.Epidemiol Infect. Year: 2008;136:577–60310.1017/S095026880700935117686195
29. . SethabutrO, EcheverriaP, HogeCW, BodhidattaL, PitarangsiCDetection of Shigella and enteroinvasive Escherichia coli by PCR in the stools of patients with dysentery in Thailand.J Diarrhoeal Dis Res. Year: 1994;12:265–97751567
30. . CaulfieldLE, de OnisM, BlössnerM, BlackREUndernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles.Am J Clin Nutr. Year: 2004;80:193–815213048

Tables
[TableWrap ID: T1] Table 1  Estimated annual number of diarrheal episodes in children 0–4 years of age, Asia, 1990–2009
Characteristic Age group
0–11 m 1–4 y 0–4 y
Total population, × 1,000 78,533 282,719 361,252
No. diarrheal episodes/child/y (15)
3.2
2.3

Total diarrheal episodes, × 1,000 251,306 650,252 901,559
At home (14,16) 221,651 597,583 819,234
At treatment facility (14,16) 29,655 52,670 82,325
In outpatient department 25,884 51,370 77,254
Hospitalized
3,771
1,300
5,071
Median caused by shigellosis, %
At home* 4.4%
In treatment facility†
5.8
9.4

Weighted mean caused by shigellosis, % (95% confidence interval)


5.1 (4.0–5.7)
No. shigellosis cases
At home, × 1,000 39,669
In treatment facility, × 1,000
1,720
4,951
6,671
Total, × 1,000 46,340
95% confidence interval of weighted mean, × 1,000 44,924–57,316

[TableWrap ID: T2] Table 2  Shigella spp.–associated diarrhea in older children and adults, Asia, 1990–2009
Characteristic Age group, y
5–14 >15
Population (× 1,000) 742,911 2,833,857
Diarrhea episodes/person/y (17)*
0.65
0.50
Total diarrhea episodes, × 1,000 482,892 1,416,929
At home 473,234 1,388,590
Treatment facility (1)†
9,658
28,339
Median caused by Shigella spp., %
At home* 4 4
At treatment facility†
11.6
10.7
Proportion caused by shigellosis (weighted mean), %
At home* 4.6 (4.0–5.1)
At treatment facility†
8.3 (7.7–9.0)
Annual no. episodes of Shigella spp.–associated diarrhea, × 1,000
At home 18,929 55,544
At treatment facility
1,120
3,032
Total no. episodes of Shigella spp.–associated diarrhea, × 1,000 20,049 58,576
95% confidence interval of weighted mean, × 1,000 19,673–24,898 57,726–73,057

[TableWrap ID: T3] Table 3  Case-fatality rates for hospitalized patients with Shigella infections, Asia, 1990–2009
Country
Area
Year
Case-fatality rate by age group
0–11 mo
1–4 y
>5 y
Bangladesh* Urban/rural 1990–1999 2.73 1.42 0.33
Bangladesh† Urban 2000–2008 1.26 0 0
Bangladesh‡ Rural 2000–2008 0.51 0.02 0
People’s Republic of China (22) Rural 2002 0 0 0
Thailand (22) Rural 2000–2003 0 0 0
Indonesia (22) Rural 2001–2003 0 0 0
Vietnam (22) Urban/rural 2001–2003 0 0 0
Pakistan (22) Rural 2002–2003 0 0 0
Bangladesh (22)
Periurban
2002–2004
0
0
0
Median 0.89 0.02 0
Weighted mean, % (95% confidence interval) 0.80 (0.59–1.03) 0.1 (0.02–0.25)

*International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDRB,B) hospital surveillance, 1990–1999.
†ICDDR,B hospital surveillance (urban), 2000–2008.
‡ICDDR,B hospital surveillance (rural), 2000–2008.


[TableWrap ID: T4] Table 4  Estimated annual number of deaths and case-fatality rates for hospitalized persons with Shigella infection, Asia, 1990–2009*
Characteristic
Age group
0–11 mo 1–4 y
No. persons with diarrhea, × 1,000† 3,771 1,300
No. persons with Shigella infection, × 1,000 (% total persons with diarrhea)† 219 (5.8) 122 (9.4)
No. Shigella spp.–related deaths (95% CI) 1,949 (1,292–2256) 24 (24–305)
Case fatality rate, %‡ 0.89 0.01
Corrected no. Shigella spp.–related deaths, × 1,000 (95% CI)§ (23,24)
13,643 (9,044–15,792)
168 (168–2,135)
Total no. Shigella spp.–related deaths (95% CI) 13,811 (9,212–17,927)

*CI, confidence interval.
†Table 1.
‡Table 3.
§Corrected for out-of-hospital deaths.



Article Categories:
  • Research
Article Categories:
  • Research

Keywords: Keywords: Bacteria, enteric infections, Shigella, shigellosis, mortality, Asia, Bangladesh, measles vaccine, vitamin A, research.

Previous Document:  Comparison of 3 infrared thermal detection systems and self-report for mass fever screening.
Next Document:  Measles virus strain diversity, Nigeria and Democratic Republic of the Congo.